Table 4.
Base-Case Results for the Markov Model (10-Year Time Horizon)
| Estimated outcomes | IABP (N = 211) | pVAD (N = 216) |
|---|---|---|
| Cost | ||
| Mean, $ | 75,655.58 | 85,896.66 |
| Minimum, $ | 71,906.62 | 2090.03 |
| Maximum, $ | 80,032.57 | 9382.27 |
| Standard deviation, $ | 1467.07 | 1285.73 |
| Effectiveness, QALYs | ||
| Mean | 2.22 | 2.48 |
| Minimum | 2.11 | 2.36 |
| Maximum | 2.34 | 2.59 |
| Standard deviation | 0.04 | 0.04 |
| Cost-effectiveness | ||
| Incremental cost, $ | 10,241.08 | |
| Incremental QALY | 0.26 | |
| Estimated ICER, $ | 39,388.77 | |
IABP indicates intra-aortic balloon pump; ICER, incremental cost-effectiveness ratio; pVAD, percutaneous ventricular assist device; QALY, quality-adjusted life-year.